Amid the topmost stocks in today’s market is Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S had a market cap of 121941.48, indicating that it has a good hold on the market value of the shares outstanding. The current market cap of Novo Nordisk A/S exhibits the basic determinant of asset allocation and risk-return parameters for its stocks.
The P/E of Novo Nordisk A/S is currently valued at 31.23 allowing its investors to analyze the company’s stock valuation and its shares relative to the income of the company that it makes. With the constructive P/E value of Novo Nordisk A/S, the investors are able to forecast the positive earnings growth of the company.
The forward P/E of Novo Nordisk A/S is at 26.04 signifying the uses of estimated net earnings over the next 12 months. Investors will be getting a good grip in comparing the current earnings of the company to estimated future earnings.
With its low price-to-sales ratio of 8, the company is evidently a better investment since the investors are paying a lower amount for each unit of sales. However, the company sales do not necessarily expose the entire picture, as it might be unprofitable with a low P/S ratio.
The price-to-book ratio of 24.07 for Novo Nordisk A/S (NYSE:NVO) implies that investors are highly hopeful for the organization to create more value from the given set of assets. The market value of the firm’s assets are considerably higher in contrast to their accounting value. The current P/B amount of Novo Nordisk A/S best indicates the value approach in differentiating good from the bad. The ratio also provides a clue to how much investors are paying for what would be left if the company went bankrupt immediately.
The target payout ratio for Novo Nordisk A/S is currently measuring at 40.60%, outlining what size the company’s dividends should be. It also demonstrates a stable dividend policy for Novo Nordisk A/S connected to the long-run, with viable earnings.
The EPS for Novo Nordisk A/S is valued at 1.88 with an EPS growth this year at 7.40%. The company’s EPS growth for the following year is valued at 13.60%, indicating an EPS value of 22.90% for the past 5 years, and an EPS value of 15.00% for the coming five years.
Novo Nordisk A/S’s sales for the past 5 years rolls at 11.70%, exhibiting an EPS growth from quarter-to-quarter at 30.60%. The sales growth of the company is 20.40% at the moment, indicating the average sales volume of the company’s products and services that have typically improved year-to-year.
Company’s existing stock price is at 58.21 with a change in price of -0.87%. As of now, the target price for the company is measuring at 60.1. Novo Nordisk A/S’s ROA is rolling at 41.30%, following the ROI of 65.50%. Quick and current ratio is valued at 1 and 1.3 respectively.